Form 4: Teva Executive Trades Shares Under 10b5-1 Plan

Teva Pharmaceutical Industries Ltd. executive Evan Lippman reported transactions involving ordinary shares and restricted share units under a pre-arranged trading plan.

Summary

• Evan Lippman, EVP of Business Development at Teva Pharmaceutical Industries Ltd., executed trades on May 14, 2026, under a Rule 10b5-1 trading plan adopted on November 10, 2025.
• The transactions involved the acquisition and disposition of ordinary shares and restricted share units (RSUs).
• Specifically, 11,841 ordinary shares were acquired and disposed of, with 5,746 shares sold to cover tax withholding obligations at a weighted average price of $35.5842.
• Additionally, 74,008 ordinary shares were acquired and disposed of, with 35,912 shares sold to cover tax withholding obligations at the same weighted average price.
• Following these transactions, Lippman beneficially owns 6,095 ordinary shares directly and 44,191 ordinary shares directly.
• RSUs granted on May 14, 2025, vested on May 14, 2026. A portion of these vested RSUs were used to cover tax withholding obligations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the reported transactions are standard insider sales executed under a pre-arranged 10b5-1 plan to cover tax obligations, rather than indicative of a change in the executive's or company's outlook.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-impactful sales.
• The sale of shares to cover tax withholding obligations is a standard and expected practice upon vesting of equity awards.

Negatives

• A significant number of shares were sold, totaling 41,658 ordinary shares (5,746 + 35,912) to cover tax withholding obligations.
• The weighted average sale price of $35.5842 reflects the market price at the time of the transaction, but the disposal of shares reduces the executive's direct holdings.

Risks

• The sale of a substantial number of shares by a key executive could be perceived negatively by the market, although it was executed under a pre-defined plan.
• Future vesting schedules for remaining RSUs could lead to further share sales if tax obligations remain significant.

Future Outlook

The filing details past transactions and does not contain forward-looking statements or guidance regarding future financial performance. However, it does outline future vesting dates for remaining RSUs, which could lead to subsequent transactions.

Management Comments

• The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
• Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
• The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.38 to $35.685, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common in the pharmaceutical industry as executives manage their compensation packages. The execution of such plans aims to provide a defense against accusations of insider trading by establishing a predetermined schedule for buying or selling securities.

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even under a 10b5-1 plan, can sometimes be interpreted as a negative signal, potentially impacting short-term share price sentiment. However, the pre-planned nature mitigates this concern.
• Employees: The transaction relates to executive compensation and does not directly impact other employees.
• Management: The transaction reflects the standard management of executive compensation and tax liabilities.

Next Steps

• Future vesting of remaining restricted share units on May 14, 2027, and May 14, 2028, may result in further transactions to cover tax withholding obligations.

Key Dates

Keywords

Teva Pharmaceutical Industries, Form 4, Insider Trading, Rule 10b5-1, Evan Lippman, Restricted Share Units, Ordinary Shares, Beneficial Ownership, Tax Withholding